Over the past 2 decades, there have been numerous stem cell studies focused on cardiac diseases, ranging from proof-ofconcept to phase 2 trials. This series of papers focuses on the legacy of these studies and the outlook for future treatment of cardiac diseases with stem cell therapies. The first section by Drs. Rosen and Myerburg is an independent review that analyzes the basic science and translational strategies supporting the rapid advance of stem cell technology to the clinic, the philosophies behind them, trial designs, and means for going forward that may impact favorably on progress. The 
We shall now revisit these viewpoints in the context of the clinical translation that has occurred during the decade since they appeared and discuss models and approaches for consideration as we move into the next decade.
"WE DO NOT KNOW WHAT CELL TO USE." (6) .
There is substantial literature regarding stem cells (7) (8) (9) (10) , and a number of stem cell types described in Rosen et al.
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Stem Cell Research to Cardiac Therapies currently in clinical studies (16, 17) we do not have that knowledge, nor have we been able to catalog the potential downsides of cell administration, the best way to prepare the cells, the impact of trying to subselect or modify them, and the best way to store, assay, or administer them (7, (51) (52) (53) .
Disease models have been created in mice, dogs, and pigs, and observations are available from patients, but we are still in midstream with regard to optimizing therapy. It also remains unclear whether there is a single optimal therapeutic model versus several different models providing target-specific therapeutic benefits.
Inconsistent standards for CSC trial enrollment.
Many cardiac patients participating in stem cell trials have had moderately-to-severely decompensated heart failure in the post-AMI or chronic ischemic heart disease setting (8, 19, 20, 46 Clinical testing strategies range from rigidly controlled randomized trials to observational strategies for defining association, causation, clinical effects, and safety.
Rosen et al.
Stem Cell Research to Cardiac Therapies is described as a prospective, randomized, phase 1b safety trial. An initial dose escalation protocol assessed the safety of CD105 þ /CD45 À autologous mononuclear cells obtained from myocardial biopsies done 2 to 4 weeks after AMI and infused into the infarct-related artery 1.5 to 3 months post-infarction.
Seventeen patients received 25,000,000 cells, whereas 8 control subjects received standard therapy.
Cardiac function was unaltered, despite significant reductions in scar mass and increased viable heart mass, regional contractility, and regional systolic wall thickening. The same investigators are now recruiting 300 patients for a phase 1-2 trial using allogeneic cells I n t e r p r e t i n g a n d r e i n t e r p r e t i n g t h e l i t e r a t u r e .
An B a l a n c i n g p a t i e n t s w i t h p a t i e n c e . forward. Medicine has seen sudden surges in progress where none might have been anticipated. But unless or until that surge happens, the landscape we face will remain challenging. would be used. This potentially offers a more consistent, accurate, and rapid path to definitive answers than has occurred to date, and (at least initially)
would require fewer patients as experimental
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Stem Cell Research to Cardiac Therapies subjects. Although issues of intellectual property and jockeying among various business interests would require resolution, I-SPY2 suggests that these can be resolved and that the overall strategy has merit.
In going forward, it should be noted that issues regarding cell fate await resolution (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) 82, 83) .
Hence, future trials of various designs might more consistently avail themselves of imaging techniques to assess cell survival (28) (29) (30) (31) . Approaches such as these may not only allow the correlation of cell survival with functional outcome, but may also enhance prospects for personalizing therapy (28) . However, this merging of roles also has lessrecognized dangers.
Experienced clinicians integrate disparate information to provide the best experience for patients.
We learn that some variables (such as blood pressure and EF) vary randomly and largely meaninglessly between visits. We may handle this milieu of uncertainty by using clinical acumen to select those values most appropriate to the overall picture: the consequences for science are not a priority at the bedside. OPTIMISM. Optimism drives us forward in clinical research, but may also, paradoxically, be silently Neither noise nor optimism alone can cause this problem: it is the combination that is deadly (97, 98 ). When automated measurements showed a much smaller effect, our community seemed determined to deny that they might be more reliable. One explanation offered was that drug trials had always shown office pressures to drop more than ambulatory pressures (101) . However, this is only true for unblinded trials, that is, with office pressures measured by staff knowing which trial arm the patient is in. When staff members are blinded, office and ambulatory measurements show identical effect sizes (101) . Thus, the rarely discussed insight from drug trials is that, unless protected by blinding, we cannot help overstating office blood pressure reductions in the active arm, because we are only human. When the large blinded randomized controlled trial of renal denervation found a far smaller blood pressure effect than previous unblinded studies, the most likely explanation was that blinding had prevented inadvertent overstatement (98) . Yet, expert analysis in our community professed confusion (102) "at the higher level" and proposed one-half dozen explanations that ignored the bias-resisting benefits of blinding. This could be a sophisticated, articulate, and expert example of denial.
WHY IS GETTING A WRONG ANSWER HARMFUL?
First, scientists or investors relying on published science may unknowingly embark on a futile path. Each data point is the measured improvement in a single patient of a clinical variable after a therapy (which happens to be ineffective). Across all patients, the average change is 0, but only if the measurements are acquired dispassionately. If, for example, 2 measurements are made and the "best" is chosen (red data points), this optimism contributes a positive bias (arrow) that may be (correctly) detected as statistically significant even though it is illusory. Noisier measurements are more vulnerable. Large study size paradoxically makes the problem worse (97, 98) .
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Stem Cell Research to Cardiac Therapies participants in cognitive dissonance (103) , that is, increasing difficulty countenancing the possibility that the effect is illusory.
Third, when our entire community tacitly accepts optimistic estimates as a convention, real scientific progress can come to a halt.
The serious impediment to progress comes from the differential ease of expanding the component rectangles in Figure 3 (104) . Suppose an exciting report arises of an unblinded cohort experiencing a high response rate (e.g., 80%). This may represent a Nobel-prize-deserving near-doubling of the genuine benefit (red component in Figure 3 ) from 16% to 30%, or a slight enlargement of the other components from 50% to 64%. Which will occur more commonly? What innovations will thereby accumulate into the "state of the art?" Is it, therefore, wise for our field to define progress by expansion of total response rate in un- Within randomized controlled trials (RCTs), the response rate in the active arm averages 51%. Placebo control arms (which receive a device but not cardiac resynchronization therapy pacing) show a response rate averaging 35%, indicating the incremental effect of pacing to be 16 percentage points. The control subjects in blinded trials report a better response than those in unblinded trials: we can use this to estimate the size of the placebo effect of device implantation. The response in the unblinded controls is not due to pacing or implantation placebo, and might be described as spontaneous improvement. Myerburg castigates "paramedical influences," but without commercial development, the potential of the field will never fully be clarified, nor will the wide dissemination of reliable products be possible.
CONCLUSIONS. Based on the previously mentioned considerations, over the last several years, it is evident that we have developed a solid basis for moving forward. Blessed to date by prevalent safety, we (fortuitously) managed to avoid the sort of debacle that derailed gene therapy for more than a decade (137) . 
